Seow Cynthia H, de Silva Shanika, Kaplan Gilaad G, Devlin Shane M, Ghosh Subrata, Panaccione Remo
University of Calgary, TRW Building, Room 6D18, Calgary, Canada.
Curr Gastroenterol Rep. 2009 Dec;11(6):509-17. doi: 10.1007/s11894-009-0077-4.
Successful management of the patient with inflammatory bowel disease (IBD) involves not only the induction and maintenance of remission, but also the optimization of the benefit-to-risk equation to achieve the greatest gain in quality of life. These risks range from intolerance to prescribed medications to potentially life-threatening sequelae (eg, sepsis) of immune suppression. A proper awareness of risk on the part of the physician and education of the patient can lead to early detection and institution of an appropriate management plan, including risk management and, optimally, primary prevention (eg, prophylactic vaccination). One should take the opportunity regularly to reassess the utility and efficacy of existing therapy, with the provision of ineffective therapies mandating urgent review. Overall, optimal management of the patient with IBD requires open dialogue between clinician and patient so that both are cognizant of the goals, benefits, and potential risks of therapy.
炎症性肠病(IBD)患者的成功管理不仅涉及诱导和维持缓解,还涉及优化获益风险比,以实现生活质量的最大提升。这些风险范围从对规定药物的不耐受到免疫抑制可能导致的危及生命的后遗症(如败血症)。医生对风险的正确认识以及对患者的教育能够促成早期发现并制定适当的管理计划,包括风险管理,最理想的是进行一级预防(如预防性接种)。应定期重新评估现有治疗的效用和疗效,对于无效的治疗需进行紧急审查。总体而言,IBD患者的最佳管理需要临床医生与患者之间进行开放的对话,以便双方都了解治疗的目标、益处和潜在风险。